SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Myers LK, Rosloniec EF, Cremer MA, Kang AH. Collagen-induced arthritis, an animal model of autoimmunity. Life Sci 1997; 61: 186178.
  • 2
    Myers LK, Tang B, Rosioniec EF, Stuart JM, Kang AH. An altered peptide ligand of type II collagen suppresses autoimmune arthritis. Crit Rev Immunol 2007; 27: 34556.
  • 3
    Brand DD, Myers LK, Whittington KB, Latham KA, Stuart JM, Kang AH, et al. Detection of early changes in autoimmune T cell phenotype and function following intravenous administration of type II collagen in a TCR-transgenic model. J Immunol 2002; 168: 4908.
  • 4
    Koch U, Radtke F. Mechanisms of T cell development and transformation [review]. Annu Rev Cell Dev Biol 2011. E-pub ahead of print.
  • 5
    Rosloniec EF, Cremer M, Kang AH, Myers LK, Brand DD. Collagen-induced arthritis. Curr Protoc Immunol 2010;Chapter 15:Unit 15. 5.125.
  • 6
    Kleinau S, Martinsson P, Heyman B. Induction and suppression of collagen-induced arthritis is dependent on distinct Fcγ receptors. J Exp Med 2000; 191: 16116.
  • 7
    Kleinau S. The impact of Fc receptors on the development of autoimmune diseases. Curr Pharm Des 2003; 9: 186170.
  • 8
    Nandakumar KS, Andren M, Martinsson P, Bajtner E, Hellstrom S, Holmdahl R, et al. Induction of arthritis by single monoclonal IgG anti-collagen type II antibodies and enhancement of arthritis in mice lacking inhibitory FcγRIIB. Eur J Immunol 2003; 33: 226977.
  • 9
    Rosloniec EF, Kang AH, Myers LK, Cremer MA. Collagen-induced arthritis. In: Coico R, Shevach E, editors. Current protocols in immunology. New York: John Wiley & Sons; 1997. p. 15.5.124.
  • 10
    Ziegler SF. FOXP3: of mice and men. Annu Rev Immunol 2006; 24: 20926.
  • 11
    Krishnan S, Juang YT, Chowdhury B, Magilavy A, Fisher CU, Nguyen H, et al. Differential expression and molecular associations of Syk in systemic lupus erythematosus T cells. J Immunol 2008; 181: 814552.
  • 12
    Myers LK, Rosloniec EF, Seyer JM, Stuart JM, Kang AH. A synthetic peptide analogue of a determinant of type II collagen prevents the onset of collagen-induced arthritis. J Immunol 1993; 150: 46528.
  • 13
    Myers LK, Tang B, Rosloniec EF, Stuart JM, Chiang TM, Kang AH. Characterization of a peptide analog of a determinant of type II collagen that suppresses collagen-induced arthritis. J Immunol 1998; 161: 358995.
  • 14
    Gershon RK, Cohen P, Hencin R, Liebhaber SA. Suppressor T cells. J Immunol 1972; 108: 58690.
  • 15
    Lehner T. Special regulatory T cell review: the resurgence of the concept of contrasuppression in immunoregulation. Immunology 2008; 123: 404.
  • 16
    Zhu J, Yamane H, Paul WE. Differentiation of effector CD4 T cell populations. Annu Rev Immunol 2010; 28: 44589.
  • 17
    Henao-Tamayo MI, Ordway DJ, Irwin SM, Shang S, Shanley C, Orme IM. Phenotypic definition of effector and memory T-lymphocyte subsets in mice chronically infected with Mycobacterium tuberculosis. Clin Vaccine Immunol 2010; 17: 61825.
  • 18
    Godfrey DI, Stankovic S, Baxter AG. Raising the NKT cell family. Nat Immunol; 11: 197206.
  • 19
    Thomson CW, Teft WA, Chen W, Lee BP, Madrenas J, Zhang L. FcRγ presence in TCR complex of double-negative T cells is critical for their regulatory function. J Immunol 2006; 177: 22507.
  • 20
    Krishnan S, Farber DL, Tsokos GC. T cell rewiring in differentiation and disease. J Immunol 2003; 171: 332531.
  • 21
    Krishnan S, Nambiar MP, Warke VG, Fisher CU, Mitchell J, Delaney N, et al. Alterations in lipid raft composition and dynamics contribute to abnormal T cell responses in systemic lupus erythematosus. J Immunol 2004; 172: 782131.
  • 22
    Chentouf M, Ghannam S, Bes C, Troadec S, Cerutti M, Chardes T. Recombinant anti-CD4 antibody 13B8.2 blocks membrane-proximal events by excluding the Zap70 molecule and downstream targets SLP-76, PLCγ1, and Vav-1 from the CD4-segregated Brij 98 detergent-resistant raft domains. J Immunol 2007; 179: 40920.
  • 23
    Chauhan A, Atkinson JP, Moore TL. Altered T cell signaling in systemic lupus erythematosus (SLE): a role for FcγRIII and immune complexes (ICs) [abstract]. Arthritis Rheum 2010; 62 Suppl: S3523.
  • 24
    Joosten LA, Lubberts E, Helsen MM, Saxne T, Coenen-de Roo CJ, Heinegard D, et al. Protection against cartilage and bone destruction by systemic interleukin-4 treatment in established murine type II collagen-induced arthritis. Arthritis Res 1999; 1: 8191.
  • 25
    Kim SH, Kim S, Evans CH, Ghivizzani SC, Oligino T, Robbins PD. Effective treatment of established murine collagen-induced arthritis by systemic administration of dendritic cells genetically modified to express IL-4. J Immunol 2001; 166: 3499505.
  • 26
    Nishibori T, Tanabe Y, Su L, David M. Impaired development of CD4+ CD25+ regulatory T cells in the absence of STAT1: increased susceptibility to autoimmune disease. J Exp Med 2004; 199: 2534.
  • 27
    Dumoutier L, Leemans C, Lejeune D, Kotenko SV, Renauld JC. Cutting edge: STAT activation by IL-19, IL-20 and mda-7 through IL-20 receptor complexes of two types. J Immunol 2001; 167: 35459.
  • 28
    Myers LK, Tang B, Stuart JM, Kang AH. The role of IL-4 in regulation of murine collagen-induced arthritis. Clin Immunol 2002; 102: 18591.
  • 29
    Tang B, Zhou J, Park JE, Cullins D, Yi AK, Kang AH, et al. T cell receptor signaling induced by an analog peptide of type II collagen requires activation of Syk. Clin Immunol 2009; 133: 14553.
  • 30
    Bielekova B, Goodwin B, Richert N, Cortese I, Kondo T, Afshar G, et al. Encephalitogenic potential of the myelin basic protein peptide (amino acids 83-99) in multiple sclerosis: results of a phase II clinical trial with an altered peptide ligand. Nat Med 2000; 6: 116775.
  • 31
    Bielekova B, Martin R. Antigen-specific immunomodulation via altered peptide ligands. J Mol Med 2001; 79: 55265.
  • 32
    Kappos L, Comi G, Panitch H, Oger J, Antel J, Conlon P, et al. Induction of a non-encephalitogenic type 2 T helper-cell autoimmune response in multiple sclerosis after administration of an altered peptide ligand in a placebo-controlled, randomized phase II trial. Nat Med 2000; 6: 117682.
  • 33
    Kim HJ, Antel JP, Duquette P, Alleva DG, Conlon PJ, Bar-Or A. Persistence of immune responses to altered and native myelin antigens in patients with multiple sclerosis treated with altered peptide ligand. Clin Immunol 2002; 104: 10514.
  • 34
    Leipe J, Skapenko A, Lipsky PE, Schulze-Koops H. Regulatory T cells in rheumatoid arthritis. Arthritis Res Ther 2005; 7: 93.
  • 35
    Prakken BJ, Samodal R, Le TD, Giannoni F, Yung GP, Scavulli J, et al. Epitope-specific immunotherapy induces immune deviation of proinflammatory T cells in rheumatoid arthritis. Proc Natl Acad Sci U S A 2004; 101: 422833.
  • 36
    Koffeman EC, Genovese M, Amox D, Keogh E, Santana E, Matteson EL, et al. Epitope-specific immunotherapy of rheumatoid arthritis: clinical responsiveness occurs with immune deviation and relies on the expression of a cluster of molecules associated with T cell tolerance in a double-blind, placebo-controlled, pilot phase II trial. Arthritis Rheum 2009; 60: 320716.